[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 21 of about 21
1. Dartnell J, Pilling J, Ferner R, Cane P, Lang-Lazdunski L: Malignant triton tumor of the brachial plexus invading the left thoracic inlet: a rare differential diagnosis of pancoast tumor. J Thorac Oncol; 2009 Jan;4(1):135-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant triton tumor of the brachial plexus invading the left thoracic inlet: a rare differential diagnosis of pancoast tumor.
  • Malignant triton tumor is a divergent malignant peripheral nerve sheath tumor with rhabdomyoblastic differentiation.
  • We report a case of malignant triton tumor arising in the brachial plexus of a 28-year-old women with neurofibromatosis type 1.
  • Fluorodeoxyglucose-positron emission tomography-computed tomography before excision demonstrated a tumor with a maximum standard uptake value of 21 at 4 hours postinjection.
  • The patient underwent complete excision of the tumor through median sternotomy and left supraclavicular approach.
  • Adjuvant radiotherapy and chemotherapy were planned but the patient died of metastatic disease within 3 months of surgical resection.
  • [MeSH-major] Brachial Plexus / pathology. Neurilemmoma / diagnosis. Pancoast Syndrome / diagnosis. Peripheral Nervous System Neoplasms / diagnosis. Thoracic Neoplasms / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Fatal Outcome. Female. Fluorodeoxyglucose F18. Humans. Magnetic Resonance Imaging. Neoplasm Invasiveness. Neurofibromatosis 1 / complications. Positron-Emission Tomography. Radiopharmaceuticals. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19096322.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


2. Meola S, Olivieri M, Mirabile C, Mastrandrea P: Anesthetic management for right upper extremity amputation due to recidivous cutaneous carcinoma and acute postoperative pain control in patients affected by epidermolysis bullosa. Minerva Anestesiol; 2010 Feb;76(2):144-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Moreover, the intraoperative brachial plexus nerve block before amputation followed by positioning of an epidural catheter to deliver continuous infusion of local anesthetics close to the cut nerves during surgery obtained a very good level of acute postoperative pain control.
  • [MeSH-major] Amputation / methods. Anesthesia. Epidermolysis Bullosa / complications. Pain, Postoperative / drug therapy. Skin Neoplasms / complications. Skin Neoplasms / surgery. Upper Extremity / surgery
  • [MeSH-minor] Anesthesia, Epidural. Anesthetics, Local / therapeutic use. Brachial Plexus / physiology. Humans. Male. Monitoring, Intraoperative. Neoplasm Recurrence, Local. Young Adult

  • Genetic Alliance. consumer health - Epidermolysis Bullosa.
  • MedlinePlus Health Information. consumer health - Anesthesia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20150856.001).
  • [ISSN] 1827-1596
  • [Journal-full-title] Minerva anestesiologica
  • [ISO-abbreviation] Minerva Anestesiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Anesthetics, Local
  •  go-up   go-down


3. Smith ER, Ott M, Wain J, Louis DN, Chiocca EA: Massive growth of a meningioma into the brachial plexus and thoracic cavity after intraspinal and supraclavicular resection. Case report and review of the literature. J Neurosurg; 2002 Jan;96(1 Suppl):107-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Massive growth of a meningioma into the brachial plexus and thoracic cavity after intraspinal and supraclavicular resection. Case report and review of the literature.
  • Involvement of peripheral nerves by meningioma, either by a primary tumor or through secondary extension of an intraaxial lesion, is a much rarer entity; there have been only two reported primary brachial plexus meningiomas and one description of secondary involvement of the brachial plexus by extension of an intraaxial lesion.
  • The authors present the case report of a 36-year-old man who was initially treated for a thoracic spinal meningioma that infiltrated the brachial plexus.
  • After resection, progressive and massive growth with infiltration of the brachial plexus and pleural cavity occurred over a 5-year period despite radio- and chemotherapy.
  • [MeSH-major] Brachial Plexus Neuropathies / surgery. Meningeal Neoplasms / surgery. Meningioma / surgery. Neoplasm Recurrence, Local / surgery. Peripheral Nervous System Neoplasms / surgery. Thoracic Neoplasms / surgery
  • [MeSH-minor] Adult. Decompression, Surgical. Fatal Outcome. Follow-Up Studies. Humans. Laminectomy. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness. Reoperation. Thoracic Vertebrae / pathology. Thoracic Vertebrae / surgery. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brachial Plexus Injuries.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11795697.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Miki M, Masaki Y, Nakamura T, Iwao H, Nakajima A, Sakai T, Sawaki T, Kawanami T, Kaito M, Kurose N, Fujita Y, Tanaka M, Fukushima T, Hirose Y, Umehara H: [Primary neurolymphomatosis of the cervical nerve root]. Rinsho Ketsueki; 2010 Jul;51(7):564-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • On (18)FDG-PET, abnormal accumulation was noted on both sides of the brachial plexus at the cervical spinal cord.
  • Following R-CHOP therapy, the abnormal accumulation of (18)FDG-PET scan disappeared.
  • Although salvage chemotherapy was performed, the patient died of overwhelming sepsis.
  • Early distinct diagnosis using (18)FDG-PET and combination chemotherapy of rituximab and high dose methotrexate may improve the outcome for such patients.
  • [MeSH-major] Cervical Vertebrae. Lymphoma, Large B-Cell, Diffuse / therapy. Peripheral Nervous System Neoplasms / therapy. Spinal Nerve Roots
  • [MeSH-minor] Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Fatal Outcome. Female. Humans. Methotrexate / administration & dosage. Neoplasm Recurrence, Local. Neurosurgical Procedures. Positron-Emission Tomography. Prednisolone / administration & dosage. Rituximab. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Neck Injuries and Disorders.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20693778.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; YL5FZ2Y5U1 / Methotrexate; VAP-cyclo protocol
  •  go-up   go-down


5. Krarup C, Crone C: Neurophysiological studies in malignant disease with particular reference to involvement of peripheral nerves. J Neurol; 2002 Jun;249(6):651-61

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neurological and neuromuscular disorders are frequent complications in patients with neoplasms and may involve the neuromuscular system, including motor and sensory nerve cell bodies, axons, myelin, neuromuscular transmission and muscle alone or in combination.
  • Electrophysiological studies are of value in delineating the type, degree and extent of involvement, and may be of assistance in pointing towards the underlying cause: paraneoplastic factors, treatment with chemotherapy or radiation or metastatic infiltration.
  • Even in cases where such studies are obtained, a final diagnosis may only be ascertained during follow up, since the neuromuscular disorders frequently occur before the neoplasm is detected.
  • [MeSH-major] Central Nervous System Diseases / etiology. Meningeal Neoplasms / secondary. Neoplasm Metastasis / physiopathology. Neoplasms / complications. Paraneoplastic Polyneuropathy / physiopathology
  • [MeSH-minor] Animals. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Brachial Plexus Neuropathies / etiology. Brachial Plexus Neuropathies / pathology. Brachial Plexus Neuropathies / physiopathology. Humans. Lumbosacral Plexus / drug effects. Lumbosacral Plexus / physiopathology. Lumbosacral Plexus / radiation effects. Neural Conduction / physiology. Radiotherapy / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12111295.001).
  • [ISSN] 0340-5354
  • [Journal-full-title] Journal of neurology
  • [ISO-abbreviation] J. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Number-of-references] 113
  •  go-up   go-down


6. Wasner G, Hilpert F, Schattschneider J, Binder A, Pfisterer J, Baron R: Docetaxel-induced nail changes--a neurogenic mechanism: a case report. J Neurooncol; 2002 Jun;58(2):167-74
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Docetaxel is a new taxoid widely used in chemotherapy for advanced breast cancer and other solid malignancies.
  • We report a patient with a complete peripheral palsy of the right arm due to advanced breast cancer with diffuse tumor infiltration of the brachial plexus.
  • Treatment with docetaxel led to onycholysis at all extremities except the paretic hand.
  • [MeSH-major] Arm. Breast Neoplasms / complications. Breast Neoplasms / drug therapy. Nail Diseases / chemically induced. Paclitaxel / adverse effects. Paclitaxel / analogs & derivatives. Paralysis / etiology. Taxoids
  • [MeSH-minor] Afferent Pathways / physiopathology. Brachial Plexus / pathology. Efferent Pathways / physiopathology. Female. Humans. Middle Aged. Motor Neurons / physiology. Neoplasm Invasiveness. Neural Conduction. Neurologic Examination. Neurons, Afferent / physiology. Parasympathetic Nervous System / physiopathology. Sensory Thresholds. Skin / innervation. Sympathetic Nervous System / physiopathology. Vibration

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Nail Diseases.
  • MedlinePlus Health Information. consumer health - Paralysis.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Physiol. 1980 Sep;306:537-52 [7463376.001]
  • [Cites] Science. 1990 Apr 20;248(4953):370-2 [1970196.001]
  • [Cites] Semin Oncol. 1995 Dec;22(6 Suppl 13):17-21 [8604448.001]
  • [Cites] Lancet. 2000 Aug 5;356(9228):507-8 [10981914.001]
  • [Cites] Mayo Clin Proc. 1983 Sep;58(9):583-92 [6310277.001]
  • [Cites] Pain. 1996 Oct;67(2-3):317-26 [8951925.001]
  • [Cites] J Clin Oncol. 1996 May;14(5):1672-8 [8622087.001]
  • [Cites] Dermatology. 1999;198(3):288-90 [10393455.001]
  • [Cites] J Clin Oncol. 1997 Sep;15(9):3149-55 [9294478.001]
  • [Cites] J Neurol. 2000 Apr;247(4):267-72 [10836618.001]
  • [Cites] Lancet. 2001 Mar 24;357(9260):910 [11289346.001]
  • [Cites] Diabet Med. 1992 Mar;9(2):166-75 [1563252.001]
  • [Cites] J Leukoc Biol. 1992 Jul;52(1):119-21 [1353517.001]
  • [Cites] Ann Oncol. 1994 Jul;5(6):527-32 [7918124.001]
  • [Cites] Neuroscience. 1995 Mar;65(1):283-91 [7753402.001]
  • [Cites] Neuroscience. 1997 Nov;81(1):255-62 [9300418.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1976 Nov;39(11):1071-5 [188989.001]
  • [Cites] Cancer. 2000 May 15;88(10):2367-71 [10820360.001]
  • [Cites] Ann Oncol. 1998 Feb;9(2):230-1 [9553674.001]
  • [Cites] Brain. 1991 Aug;114 ( Pt 4):1819-26 [1884180.001]
  • [Cites] Ann Pharmacother. 1999 May;33(5):584-6 [10369623.001]
  • [Cites] J Auton Nerv Syst. 1996 Sep 12;60(3):147-53 [8912264.001]
  • [Cites] Brain. 1993 Dec;116 ( Pt 6):1477-96 [8293282.001]
  • [Cites] Bibl Anat. 1965;7:314-24 [5860752.001]
  • [Cites] Muscle Nerve. 1993 Jul;16(7):757-68 [8505932.001]
  • [Cites] Muscle Nerve. 1992 Apr;15(4):507-12 [1565120.001]
  • [Cites] Ann Oncol. 1993 Aug;4(7):610-1 [8103352.001]
  • [Cites] J Am Acad Dermatol. 1984 Feb;10(2 Pt 1):250-8 [6371069.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1991 Nov;54(11):965-71 [1800668.001]
  • [Cites] J Neurosci. 1997 May 1;17(9):3234-8 [9157197.001]
  • [Cites] Rev Physiol Biochem Pharmacol. 1992;121:49-146 [1485073.001]
  • [Cites] Lancet. 2000 Apr 1;355(9210):1176-8 [10791395.001]
  • [Cites] J Physiol. 1992 Mar;448:749-64 [1593488.001]
  • [Cites] Arch Dermatol. 1998 Sep;134(9):1167-8 [9762045.001]
  • (PMID = 12164689.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


7. Murakami M, Kuroda Y, Nishimura S, Sano A, Okamoto Y, Taniguchi T, Nakajima T, Kobashi Y, Matsusue S: Intraarterial infusion chemotherapy and radiotherapy with or without surgery for patients with locally advanced or recurrent breast cancer. Am J Clin Oncol; 2001 Apr;24(2):185-91
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraarterial infusion chemotherapy and radiotherapy with or without surgery for patients with locally advanced or recurrent breast cancer.
  • We analyzed response, side effects, and local control rates of a multimodal treatment consisting of intraarterial infusion chemotherapy (IAIC) and radiotherapy with or without surgery for patients with locally advanced or recurred breast cancer.
  • IAIC started as initial treatment up to three times maximum.
  • After IAIC, patients in primary cases underwent radical mastectomy or breast conservation surgery, after radiotherapy at a total dose of 50 Gy/25 fractions/5 weeks with a boost of 10 Gy.
  • Despite a high rate of residual positive margin (67%) or clinically residual carcinoma, local recurrence developed only in 2 patients (6%) and local control rates at 5 years were calculated as 89%.
  • Skin ulcer (6%), brachial plexus neuropathy (3%), and radiation pneumonitis (3%) occurred as late toxicity.
  • IAIC was effective as an induction treatment and radiotherapy played a role of local control for patients with locally advanced or recurrent breast cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Breast Neoplasms / drug therapy. Breast Neoplasms / radiotherapy. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Infusions, Intra-Arterial. Middle Aged. Neoplasm Staging. Radiotherapy Dosage. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11319296.001).
  • [ISSN] 0277-3732
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Qayyum A, MacVicar AD, Padhani AR, Revell P, Husband JE: Symptomatic brachial plexopathy following treatment for breast cancer: utility of MR imaging with surface-coil techniques. Radiology; 2000 Mar;214(3):837-42
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Symptomatic brachial plexopathy following treatment for breast cancer: utility of MR imaging with surface-coil techniques.
  • PURPOSE: To investigate the clinical utility and diagnostic accuracy of magnetic resonance (MR) imaging in patients with symptomatic brachial plexopathy following treatment for breast cancer.
  • MATERIALS AND METHODS: Fifty patients with symptoms of brachial plexopathy (principally pain, weakness, and paresthesia) who had received treatment for breast cancer, which included surgery, radiation therapy, and cytotoxic chemotherapy, underwent MR imaging at 1.5 T.
  • MR imaging was performed by using a body coil, which was supplemented with surface-coil imaging of the cervical spine and shoulder-coil imaging of the brachial plexus.
  • At review, two observers attempted to discriminate between tumor recurrence and nonmalignant causes of symptoms.
  • RESULTS: Of 27 patients demonstrated to have tumor recurrence, 26 were correctly identified by using MR imaging; the recurrence was directly related to the brachial plexus in 17.
  • The MR criteria used for detection of tumor yielded a sensitivity of 96%, specificity of 95%, positive predictive value of 96%, and negative predictive value of 95%.
  • CONCLUSION: MR imaging is reliable and accurate in the diagnosis of symptomatic brachial plexopathy following breast cancer therapy.
  • [MeSH-major] Brachial Plexus Neuropathies / diagnosis. Breast Neoplasms / therapy. Magnetic Resonance Imaging
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Brachial Plexus / pathology. Combined Modality Therapy. Female. Humans. Image Enhancement. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / diagnosis. Sensitivity and Specificity


9. von Falck C, Rodt T, Joerdens S, Waldeck S, Kiesel H, Knapp WH, Galanski M: F-18 2-fluoro-2-deoxy-glucose positron emission tomography/computed tomography for the detection of radicular and peripheral neurolymphomatosis: correlation with magnetic resonance imaging and ultrasound. Clin Nucl Med; 2009 Aug;34(8):493-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] F-18 2-fluoro-2-deoxy-glucose positron emission tomography/computed tomography for the detection of radicular and peripheral neurolymphomatosis: correlation with magnetic resonance imaging and ultrasound.
  • As blind nerve biopsy is invasive and may be false negative, surrogate criteria for the diagnosis of neurolymphomatosis have been proposed based on magnetic resonance imaging/computed tomography findings.
  • Recently, a few reports have been published that discuss a possible advantage of F-18 2-fluoro-2-deoxy-glucose positron emission tomography/computed tomography (F-18 FDG PET/CT) in these patients.We report the case of a 41-year-old man who presented with progressive tetraparesis and dysaesthesia, in which F-18 FDG PET/CT aided to the diagnosis of neurolymphomatosis due to a large B-cell lymphoma.
  • The patient received chemotherapy (R-CHOP) and the neurologic symptoms were clearly regressive.
  • Three months after the end of systemic chemotherapy the patient presented again with progressive neurologic symptoms.
  • Additional ultrasound and magnetic resonance imaging examinations were performed and confirmed infiltration of the left brachial plexus, the right femoral, and the right sciatic nerve.We present this case to support the hypothesis that F-18 FDG PET/CT is a valuable imaging modality in patients with suspected neurolymphomatosis.
  • [MeSH-minor] Adult. Humans. Magnetic Resonance Imaging. Male. Neoplasm Staging. Positron-Emission Tomography. Recurrence. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19617723.001).
  • [ISSN] 1536-0229
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


10. Sekar R, Stone PR: Trastuzumab use for metastatic breast cancer in pregnancy. Obstet Gynecol; 2007 Aug;110(2 Pt 2):507-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Trastuzumab is approved for first-line treatment for breast cancer in combination with docetaxel for stage 2 tumors positive for human epidermal growth factor receptor 2.
  • She underwent two cycles of chemotherapy, and an ultrasound scan at 30 weeks showed anhydramnios.
  • Reappearance of amniotic fluid was noted at 33 weeks of gestation, 7 weeks after cessation of treatment.
  • CONCLUSION: Treatment with trastuzumab during midgestation may be associated with anhydramnios.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Breast Neoplasms / drug therapy. Carcinoma, Ductal, Breast / drug therapy. Oligohydramnios / chemically induced. Pregnancy Complications, Neoplastic / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Humanized. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brachial Plexus Neuropathies / drug therapy. Chemotherapy, Adjuvant. Female. Humans. Infant, Newborn. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Neoplasm Staging. Pregnancy. Pregnancy Outcome. Taxoids / adverse effects. Taxoids / therapeutic use. Trastuzumab


11. Goubier JN, Teboul F, Oberlin C: [Desmoid tumors and brachial plexus]. Chir Main; 2003 Aug;22(4):203-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Desmoid tumors and brachial plexus].
  • [Transliterated title] Tumeurs desmoïdes et plexus brachial.
  • The aim of our paper is to assess the functional results and specific difficulties encountered in the treatment of desmoid tumors located near the brachial plexus.
  • Seven patients with a desmoid tumor in this region were followed for at least 2 years (average 59 months).
  • Three patient had postoperatively chemotherapy and 1 patient had radiation therapy.
  • The margins of desmoid tumor resection have to be wide to avoid local recurrence.
  • However, nerves and blood vessels have to be preserved in order to maintain upper limb function and there may well be a need for adjuvant therapy.
  • [MeSH-major] Brachial Plexus. Fibromatosis, Aggressive / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14611074.001).
  • [ISSN] 1297-3203
  • [Journal-full-title] Chirurgie de la main
  • [ISO-abbreviation] Chir Main
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 10
  •  go-up   go-down


12. Papanastassiou I, Ioannou M, Magoulas D, Lalos S, Athanassiou AE, Ziras N, Thanopoulou E, Demertzis N: Chemoembolization facilitates limb salvage surgery in stage III soft tissue sarcoma. J BUON; 2009 Jul-Sep;14(3):507-10
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoembolization facilitates limb salvage surgery in stage III soft tissue sarcoma.
  • A 26 year-old male was referred to our unit because of a stage III soft tissue sarcoma in the shoulder girdle-axillary area and reduced forearm-distal arm strength.
  • Imaging studies revealed that the tumor encompassed the axillary artery and brachial plexus.
  • The patient received adjuvant chemotherapy (ifosfamide/mesna, adriamycin, and dacarbazine/MAID) and finally radiation therapy (RT; 6500 cGy total dose).
  • In stage III soft tissue sarcomas, especially in proximity with major nerve/arterial bundles, a multimodality approach is mandatory; chemoembolization is very effective in shrinking the tumor and defining its margins so as to make feasible a LSS.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Embolization, Therapeutic. Limb Salvage. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adult. Antibiotics, Antineoplastic / therapeutic use. Antineoplastic Agents, Alkylating / therapeutic use. Antineoplastic Agents, Phytogenic / therapeutic use. Chemotherapy, Adjuvant. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Humans. Male. Neoplasm Staging. Radiotherapy, Adjuvant. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19810146.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


13. Rivera JA, Christopoulos S, Small D, Trifiro M: Hormonal manipulation of benign metastasizing leiomyomas: report of two cases and review of the literature. J Clin Endocrinol Metab; 2004 Jul;89(7):3183-8
Hazardous Substances Data Bank. RALOXIFENE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most commonly affected organs are the lungs, but BMLs have been reported in lymph nodes, deep soft tissues, mesentery, bones, the central nervous system, and the heart.
  • Radical interventions, such as extensive tumor debulking and oophorectomy for hormonal control, although effective in many cases, are not always possible or desirable and carry significant morbidity.
  • Here we present two cases of BMLs to illustrate the role of newer therapeutic agents, the estrogen receptor modulators and the aromatase inhibitors, in the hormonal manipulation of these tumors.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Brachial Plexus Neuropathies / drug therapy. Enzyme Inhibitors / therapeutic use. Leiomyoma / drug therapy. Leiomyoma / pathology. Lung Neoplasms / secondary. Uterine Neoplasms / pathology
  • [MeSH-minor] Adult. Aromatase Inhibitors. Estrogen Receptor Modulators / therapeutic use. Female. Gonadotropin-Releasing Hormone / agonists. Humans. Magnetic Resonance Imaging. Middle Aged. Neoplasm Invasiveness. Neoplasms / diagnosis. Neoplasms / drug therapy. Nitriles / therapeutic use. Radiography, Thoracic. Raloxifene Hydrochloride / therapeutic use. Selective Estrogen Receptor Modulators / therapeutic use. Triazoles / therapeutic use

  • MedlinePlus Health Information. consumer health - Brachial Plexus Injuries.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • Hazardous Substances Data Bank. ANASTROZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15240591.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Aromatase Inhibitors; 0 / Enzyme Inhibitors; 0 / Estrogen Receptor Modulators; 0 / Nitriles; 0 / Selective Estrogen Receptor Modulators; 0 / Triazoles; 2Z07MYW1AZ / anastrozole; 33515-09-2 / Gonadotropin-Releasing Hormone; 4F86W47BR6 / Raloxifene Hydrochloride
  • [Number-of-references] 53
  •  go-up   go-down


14. Pitz CC, de la Rivière AB, van Swieten HA, Duurkens VA, Lammers JW, van den Bosch JM: Surgical treatment of Pancoast tumours. Eur J Cardiothorac Surg; 2004 Jul;26(1):202-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of Pancoast tumours.
  • Due to its localisation in the apex of the lung with invasion of the lower part of the brachial plexus, first ribs, vertebrae, subclavian vessels or stellate ganglion, a superior sulcus tumour causes characteristic symptoms, like arm or shoulder pain or Horner's syndrome.
  • Shaw and Paulson introduced combined modality treatment and for many years, this combination of radiotherapy and surgery was the treatment of choice with a mean 5-year survival of approximately 30%.
  • This method facilitates better exposure of the extreme apex of the lung, brachial plexus and subclavian vessels.
  • Also the addition of other chemotherapy agents or biologic agents such as angiogenesis inhibitors or tyrosine kinase inhibitors gives a new perspective in the treatment of Pancoast tumours.
  • [MeSH-minor] Combined Modality Therapy. Humans. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Survival Analysis. Treatment Outcome

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15201002.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 54
  •  go-up   go-down


15. Girard N, Mornex F: [Therapeutic strategies in superior sulcus tumors: a model for combined modality therapy in non-small cell lung cancer]. Cancer Radiother; 2007 Jan-Feb;11(1-2):59-66
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic strategies in superior sulcus tumors: a model for combined modality therapy in non-small cell lung cancer].
  • [Transliterated title] Traitement des tumeurs de l'apex: un modèle de stratégie multimodale dans les cancers bronchiques localement évolués.
  • Superior sulcus tumors have been individualized among other non-small cell lung cancers because of their characteristic clinical presentation in connection with their local extension to the chest wall and the brachial plexus.
  • For a long time considered as marginally resectable, superior sulcus tumors have been treated since the early 1960's, with a combined approach including preoperative radiotherapy and curative-intent surgery.
  • Two recent phase II trials showed the benefit, both regarding resectability and local control rates, and survival of combined therapeutic strategies including induction platinum-based chemoradiation, extensive surgical resection, and adjuvant chemotherapy.
  • Adjuvant radiotherapy is not recommended at the time, but needs to be re-evaluated regarding its recent technical optimisation.
  • Similarly to other locally advanced non-small cell lung cancers, exclusive chemoradiation is the standard treatment of unresectable superior sulcus tumors.
  • In this way, radiotherapy has shown to offer a prolonged analgesia in more than 75% of cases, and is associated with concurrent or sequential chemotherapy, with comparable results to those observed in stage III lung cancer.
  • These developments make superior sulcus tumors a therapeutic model for locally advanced non-small cell lung cancer, whereby the benefit of combined multimodal strategies including induction chemoradiation and surgical resection are currently evaluated in phase III trials.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / therapy. Lung Neoplasms / therapy. Neoadjuvant Therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Humans. Neoplasm Recurrence, Local / prevention & control. Neoplasm Staging. Pneumonectomy. Prognosis. Radiotherapy, Adjuvant. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17197220.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 60
  •  go-up   go-down


16. Lee YC, Lee JW: Innovative treatment for huge nuchal desmoid tumour: a case report with a 2-year follow-up. J Plast Reconstr Aesthet Surg; 2010 Aug;63(8):e622-6
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Innovative treatment for huge nuchal desmoid tumour: a case report with a 2-year follow-up.
  • BACKGROUND: The desmoid tumour is a monoclonal neoplasm originating from musculoaponeurotic tissues.
  • Surgical resection, radiotherapy, chemotherapy, hormonal therapy, non-steroidal anti-inflammatory drugs and even a wait-and-see policy, either alone or in combination, were advocated as treatment modalities.
  • Its intimacy with the carotid artery, jugular vein and brachial plexus made margin-free resection infeasible.
  • METHODS: In an effort to prevent uncontrollable tumour bleeding, we embarked on a series of strategic measures, including pre-surgical embolisation, innovative tourniquet technique, a novel method of ligature deployment, staged tumour excision and adjunct methods, such as ethanol injection and irradiation therapy.
  • [MeSH-major] Embolization, Therapeutic / methods. Fibromatosis, Aggressive / therapy. Head and Neck Neoplasms / therapy. Suture Techniques / instrumentation. Tourniquets
  • [MeSH-minor] Female. Follow-Up Studies. Humans. Neck Dissection / methods. Time Factors. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 British Association of Plastic, Reconstructive and Aesthetic Surgeons. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 20304713.001).
  • [ISSN] 1878-0539
  • [Journal-full-title] Journal of plastic, reconstructive & aesthetic surgery : JPRAS
  • [ISO-abbreviation] J Plast Reconstr Aesthet Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


17. Mok TS, Kwan WH, Yeo WM, Chan AT, Chan EC, Chak K, Chow DL, Lo C, Leung TW, Teo PM: Clinical outcomes of post-operative locoregional radiotherapy in pre-menopausal and post-menopausal Chinese women with breast cancer. Radiother Oncol; 2000 Mar;54(3):201-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patients were stratified according to tumor size, menopausal and LN status.
  • Distribution of tumor size and LN status of the two groups was similar.
  • Long-term toxicities included skin atrophy (0.3%), telangectasia (3.3%), pneumonitis (2.8%) and brachial plexus palsy (1.3%).
  • Limited use of adjuvant system chemotherapy may account, at least in part, for this finding.
  • [MeSH-major] Breast Neoplasms / radiotherapy. Postmenopause. Premenopause
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. China. Combined Modality Therapy. Female. Humans. Lymphatic Metastasis. Mastectomy. Middle Aged. Neoplasm Recurrence, Local. Radiation Injuries. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10738077.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] IRELAND
  •  go-up   go-down


18. Wahl RL: Current status of PET in breast cancer imaging, staging, and therapy. Semin Roentgenol; 2001 Jul;36(3):250-60
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current status of PET in breast cancer imaging, staging, and therapy.
  • PET can depict internal mammary nodes, but the accuracy of the method in this setting is not known, nor is there consensus on how identifying internal mammary node metastases will change treatment.
  • PET seems very well suited to detecting recurrences in soft tissues and the brachial plexus region in particular.
  • The utility of PET in planning the treatment of individual patients appears promising.
  • Although results must be confirmed in larger studies, it appears safe to conclude that failure of a chemotherapy regimen to decrease FDG uptake promptly in a breast cancer portends poor response.
  • This does not hold true for hormonal therapy.
  • However, in larger primary tumors, the ability to use PET for staging and to plan treatment response suggest it will be more widely used.
  • [MeSH-major] Breast Neoplasms / radionuclide imaging. Tomography, Emission-Computed
  • [MeSH-minor] Humans. Neoplasm Metastasis. Neoplasm Staging

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11475071.001).
  • [ISSN] 0037-198X
  • [Journal-full-title] Seminars in roentgenology
  • [ISO-abbreviation] Semin Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 67
  •  go-up   go-down


19. Molloy FM, Floeter MK, Syed NA, Sandbrink F, Culcea E, Steinberg SM, Dahut W, Pluda J, Kruger EA, Reed E, Figg WD: Thalidomide neuropathy in patients treated for metastatic prostate cancer. Muscle Nerve; 2001 Aug;24(8):1050-7
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sixty-seven men with metastatic androgen-independent prostate cancer in an open-label trial of oral thalidomide underwent neurologic examinations and nerve conduction studies (NCS) prior to and at 3-month intervals during treatment.
  • Thalidomide was discontinued in 55 patients for lack of therapeutic response.
  • Six patients developed neuropathy.
  • The SNAP index can be used to monitor peripheral neuropathy, but not for early detection.
  • [MeSH-major] Peripheral Nervous System Diseases / chemically induced. Peripheral Nervous System Diseases / diagnosis. Prostatic Neoplasms / drug therapy. Thalidomide / adverse effects
  • [MeSH-minor] Action Potentials / drug effects. Age Factors. Aged. Aged, 80 and over. Brachial Plexus / drug effects. Brachial Plexus / physiopathology. Cohort Studies. Dose-Response Relationship, Drug. Electrodiagnosis. Electromyography. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Metastasis. Neural Conduction / drug effects. Neurons, Afferent / drug effects. Prospective Studies. Risk Factors. Sural Nerve / drug effects. Sural Nerve / physiopathology


20. Ball C, Thomson KR, Kavnoudias H: Irreversible electroporation: a new challenge in "out of operating theater" anesthesia. Anesth Analg; 2010 May 1;110(5):1305-9
Hazardous Substances Data Bank. Isoflurane .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A clinical trial of IRE as a tumor ablation therapy was performed at our institution.
  • A pulsating direct current of 20 to 50 A and 500 to 3000 V was delivered into metastatic or primary tumors in the liver, kidney, or lung via needle electrodes inserted under computed tomography (CT) or ultrasound guidance.
  • Two patients developed positional neuropraxia because of the extended arm position requested for CT scanning.
  • After experimentation, we have developed a modified arm position.
  • Some patients developed self-limiting ventricular tachycardias that are now minimized by using an electrocardiogram synchronizer.
  • Three patients developed pneumothoraces as a result of the needle electrode insertion.
  • Attention to the position of the arms is required to maximize CT scan quality but minimize brachial plexus strain.
  • [MeSH-major] Electroporation / methods. Neoplasms / therapy
  • [MeSH-minor] Acid-Base Imbalance / etiology. Adult. Aged. Aged, 80 and over. Anesthesia, General. Anesthetics, Inhalation. Anesthetics, Intravenous. Arrhythmias, Cardiac / etiology. Electrocardiography. Electrodes. Electroencephalography / drug effects. Female. Humans. Hypertension / etiology. Isoflurane. Male. Middle Aged. Muscle, Skeletal / physiology. Neoplasm Metastasis / therapy. Pain, Postoperative / epidemiology. Pneumothorax / etiology. Propofol. Tomography, X-Ray Computed. Water-Electrolyte Imbalance / etiology

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. PROPOFOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Anesth Analg. 2010 May 1;110(5):1264 [20418290.001]
  • (PMID = 20142349.001).
  • [ISSN] 1526-7598
  • [Journal-full-title] Anesthesia and analgesia
  • [ISO-abbreviation] Anesth. Analg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anesthetics, Inhalation; 0 / Anesthetics, Intravenous; CYS9AKD70P / Isoflurane; YI7VU623SF / Propofol
  •  go-up   go-down


21. Boes M, Pels H, Klockgether T, Koch A, Schlegel U: High-grade B-cell NHL of the brachial plexus followed by infiltration of the spinal cord. J Neurol; 2008 Jan;255(1):135-7
MedlinePlus Health Information. consumer health - Brachial Plexus Injuries.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-grade B-cell NHL of the brachial plexus followed by infiltration of the spinal cord.
  • [MeSH-major] Brachial Plexus Neuropathies / etiology. Brachial Plexus Neuropathies / pathology. Lymphoma, B-Cell / complications. Lymphoma, B-Cell / pathology. Neoplasm Invasiveness / pathology. Spinal Cord Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Arm / innervation. Arm / physiopathology. Brachial Plexus / pathology. Brachial Plexus / physiopathology. Cavernous Sinus Thrombosis / etiology. Cavernous Sinus Thrombosis / pathology. Cavernous Sinus Thrombosis / physiopathology. Cranial Nerve Diseases / etiology. Cranial Nerve Diseases / pathology. Cranial Nerve Diseases / physiopathology. Fatal Outcome. Female. Ganglia, Spinal / pathology. Ganglia, Spinal / physiopathology. Humans. Magnetic Resonance Imaging. Middle Aged. Muscle Weakness / etiology. Muscle Weakness / physiopathology. Neoplasm Metastasis / drug therapy. Neoplasm Metastasis / pathology. Neoplasm Metastasis / physiopathology. Spinal Cord / pathology. Spinal Cord / physiopathology. Spinal Nerve Roots / pathology. Spinal Nerve Roots / physiopathology. Treatment Failure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2000 Sep;24(9):1257-65 [10976700.001]
  • [Cites] Neurosurgery. 1997 Mar;40(3):618-21; discussion 621-2 [9055305.001]
  • [Cites] J Neurosurg. 2000 Jan;92(1):165-9 [10616097.001]
  • [Cites] Auris Nasus Larynx. 1999 Jul;26(3):337-42 [10419043.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4471-3 [14597745.001]
  • (PMID = 17994311.001).
  • [ISSN] 0340-5354
  • [Journal-full-title] Journal of neurology
  • [ISO-abbreviation] J. Neurol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Germany
  •  go-up   go-down






Advertisement